HM
The startup is developing epigenetic therapies using clinically validated p38 MAP kinase inhibitors and other small molecules to provide functional cures for patients with Friedreich's Ataxia. This approach aims to advance treatment options in the healthcare industry, similar to breakthroughs achieved in Cystic Fibrosis.
Updated 3 months ago
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup is developing epigenetic therapies using clinically validated p38 MAP kinase inhibitors and other small molecules to provide functional cures for patients with Friedreich's Ataxia. This approach aims to advance treatment options in the healthcare industry, similar to breakthroughs achieved in Cystic Fibrosis.